Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer
This study has been completed.
Study NCT00129844   Information provided by Pharmacyclics

First Received on August 10, 2005.   Last Updated on August 19, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Adenocarcinoma
Non-Small-Cell Lung Carcinoma
Lung Neoplasms
Additional conditions recognized in this trial
Adenocarcinoma, Mucinous
Carcinoma
Carcinoma, Non-Small-Cell Lung
Neoplasms
More general conditions related to this trial
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Cystic, Mucinous, and Serous
Neoplasms, Glandular and Epithelial
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Interventions listed in this trial
Motexafin Gadolinium
More general drug interventions related to this trial
Antineoplastic Agents
Dermatologic Agents
Pharmacologic Actions
Photosensitizing Agents
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
Pharmacyclics


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services